What’s an OTC drugmaker worth in the race to the top of the consumer healthcare space? Potentially more than $5.3 billion, if that drugmaker is Belgium’s Omega Pharma.
The up-for-sale company has so far drawn interest from suitors including Perrigo ($PRGO) and Boehringer Ingelheim, and the big guns – Bayer and Sanofi ($SNY) – may get involved, too, Bloomberg‘s sources say. According to those sources, the sale – still in its early stages – could bring in more than €4 billion.
With €1.2 billion in first-half sales this year, Omega could add some top-line firepower for any drugmaker looking to build its presence in the consumer health arena. The company boasts about 2,000 brands, according to its website, including painkiller Solpadeine.
Bayer and Sanofi have both shown quite a bit of recent interest in doing just that. Marijn Dekkers, the German pharma’s CEO, has said many times that his company’s aim is to be the world’s OTC leader, a goal it furthered with a May deal to pick up Merck’s ($MRK) consumer unit for $14.2 billion.
Sanofi, too, has beefed up its consumer lineup considerably over the past several years, more than doubling its sales in that department between 2008 and 2012. That growth spurt included a $1.9 billion buyout of U.S.-based Chattem and a key OTC launch for allergy med Allegra.
Perrigo hasn’t shied away from M&A lately, either, though last year’s $8.6 billion deal for Irish drugmaker Elan ($ELN) didn’t further any OTC aims. Instead, the then-Michigan-based company picked up a new Dublin address in an inversion deal that slashed its tax rates.
By Carly Helfand
Source: Fierce Pharma
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
